Latest Articles
Case 1: Advanced and Recurrent MMRd Endometrioid Adenocarcinoma of the Uterus - The ASCO Post
Case 1: Advanced and Recurrent MMRd Endometrioid Adenocarcinoma of the Uterus The ASCO Post
Published: April 26, 2026, 9 p.m.
REGN5668 Combo Yields Preliminary Activity in Recurrent Ovarian/Endometrial Cancer - CancerNetwork
REGN5668 Combo Yields Preliminary Activity in Recurrent Ovarian/Endometrial Cancer CancerNetwork
Published: April 14, 2026, 8:09 p.m.
HER2 ADC Shows Promise in Recurrent Endometrial Cancer - Medscape
HER2 ADC Shows Promise in Recurrent Endometrial Cancer Medscape
Published: April 14, 2026, 11:41 a.m.
BioNTech Reports Strong Phase 2 Data for HER2-Targeted ADC in Recurrent Endometrial Cancer - TipRanks
BioNTech Reports Strong Phase 2 Data for HER2-Targeted ADC in Recurrent Endometrial Cancer TipRanks
Published: April 13, 2026, 12:29 p.m.
Data From the CARE Trial in Recurrent/Advanced Endometrial Cancer - OncLive
Data From the CARE Trial in Recurrent/Advanced Endometrial Cancer OncLive
Published: April 12, 2026, 9:28 p.m.
Dr Yang on the Activity of Cadonilimab/Chemo in Recurrent/Advanced Endometrial Carcinoma - OncLive
Dr Yang on the Activity of Cadonilimab/Chemo in Recurrent/Advanced Endometrial Carcinoma OncLive
Published: April 12, 2026, 9:10 p.m.
Cadonilimab Plus Chemotherapy Shows Strong Efficacy and Safety in Advanced or Recurrent Endometrial Cancer - OncLive
Cadonilimab Plus Chemotherapy Shows Strong Efficacy and Safety in Advanced or Recurrent Endometrial Cancer OncLive
Published: April 12, 2026, 2:35 p.m.
Dr O'Cearbhaill on the Evaluation of REGN5668 in Recurrent Ovarian or Endometrial Cancer - OncLive
Dr O'Cearbhaill on the Evaluation of REGN5668 in Recurrent Ovarian or Endometrial Cancer OncLive
Published: April 12, 2026, 12:58 a.m.
Abemaciclib Plus Letrozole Displays Durable Activity in Advanced/Recurrent Endometrioid Endometrial Carcinoma - OncLive
Abemaciclib Plus Letrozole Displays Durable Activity in Advanced/Recurrent Endometrioid Endometrial Carcinoma OncLive
Published: April 11, 2026, 4:04 p.m.
BioNTech and DualityBio’s Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer - The Manila Times
BioNTech and DualityBio’s Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer The Manila Times
Published: April 11, 2026, 11:01 a.m.
Link copied to clipboard!